Obrixtamig and ZL-1310 for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs, Obrixtamig and ZL-1310, in people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer, large cell neuroendocrine lung cancer, or another neuroendocrine cancer that has spread or come back after treatment.
- If your tumor has mixed cell types, at least half must be neuroendocrine or small cell.
- You must have already tried at least one round of platinum-based chemotherapy unless you cannot take it for medical reasons.
- For part of the study, you must have extensive-stage small cell lung cancer that has not been treated with chemotherapy yet.
- You must be 18 or older and willing to follow the study schedule and tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new treatment for advanced large-cell neuroendocrine cancer of the lung, a rare type of lung cancer. You may qualify if you've had one round of standard chemotherapy and your cancer has not improved with other treatments.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.